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Abstract
Background: In the PREVention and Acute treatment of chronic cluster headache (PREVA) study, attack frequency
reductions from baseline were significantly more pronounced with non-invasive vagus nerve stimulation plus
standard of care (nVNS + SoC) than with SoC alone. Given the intensely painful and frequent nature of chronic
cluster headache attacks, additional patient-centric outcomes, including the time to and level of therapeutic
response, were evaluated in a post hoc analysis of the PREVA study.
Findings: After a 2-week baseline phase, 97 patients with chronic cluster headache entered a 4-week randomised
phase to receive nVNS + SoC (n = 48) or SoC alone (n = 49). All 92 patients who continued into a 4-week extension
phase received nVNS + SoC. Compared with SoC alone, nVNS + SoC led to a significantly lower mean weekly attack
frequency by week 2 of the randomised phase; the attack frequency remained significantly lower in the nVNS + SoC
group through week 3 of the extension phase (P < 0.02). Attack frequencies in the nVNS + SoC group were
significantly lower at all study time points than they were at baseline (P < 0.05). Response rates were significantly
greater with nVNS + SoC than with SoC alone when response was defined as attack frequency reductions of ≥25%,
≥50%, and ≥75% from baseline (≥25% and ≥50%, P < 0.001; ≥75%, P = 0.009). The 100% response rate was 8% with
nVNS + SoC and 0% with SoC alone.
Conclusions: Prophylactic nVNS led to rapid, significant, and sustained reductions in chronic cluster headache attack
frequency within 2 weeks after its addition to SoC and was associated with significantly higher ≥25%, ≥50%, and
≥75% response rates than SoC alone. The rapid decrease in weekly attack frequency justifies a 4-week trial period to
identify responders to nVNS, with a high degree of confidence, among patients with chronic cluster headache.
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Background
Cluster headache (CH) imposes a substantial health care
burden and affects approximately 1 in 1000 individuals
worldwide [1–3], with chronic cluster headache (cCH)
comprising 10% to 15% of cases [4]. Patients with cCH
experience many intense attacks, which have been
described as the worst possible pain one can experience
[4, 5]. Clinical studies and evidence-based guidelines on
CH prophylaxis are limited, and few prophylactic
treatment options are available for this condition [6–9].
Lithium is the only prophylactic medication currently
approved for CH (only in Germany); however, there is a
lack of rigorous, randomised, controlled studies of this
drug and other treatments such as verapamil and topira-
mate, which are used off-label for CH attack prevention
[6, 10, 11].
The PREVention and Acute treatment of chronic clus-
ter headache (PREVA) study of non-invasive vagus nerve
stimulation (nVNS) (gammaCore®; electroCore, LLC;
Basking Ridge, NJ, USA) used adjunctively with standard
of care (SoC) is the largest cCH prophylaxis trial to
show significant treatment effects [6, 12]. The primary
end point of PREVA was achieved, demonstrating a sig-
nificantly more pronounced reduction from baseline in
weekly attack frequency with nVNS + SoC than with
SoC alone and yielding a mean therapeutic benefit of 3.9
fewer attacks per week (P = 0.02) [12]. Secondary end
points were also met for patients in the nVNS + SoC
group; 40% had a ≥50% reduction in weekly attack fre-
quency, and a 57% reduction from baseline in abortive
medication/oxygen use was observed (P < 0.001) [12].
Economic analyses of PREVA from German and UK per-
spectives demonstrated that nVNS + SoC was more cost-
effective when compared with SoC alone [13].
An increasing interest in clinically informative and
patient-centric outcomes, including the time to and level
of therapeutic response, has been identified in the litera-
ture [4, 14, 15]. These outcomes are improving the
ability of health care professionals and payers to assess
the clinical significance of observed treatment benefits
[4, 14, 15]. Randomised controlled studies of several
emerging therapies for primary headache have expanded
the definition of responder rate to include various levels
of response (i.e. ≥25%, ≥50%, ≥75%, and 100%) [14–17].
A treatment’s capacity for faster onset and higher levels
of response may be of particular importance for patients
with CH because of the excruciating nature and thera-
peutic urgency of the associated pain [18, 19]. Here, we
report a post hoc analysis of PREVA to further investi-
gate the time to therapeutic benefit onset and the re-
sponse rate levels associated with adjunctive nVNS used
in cCH prophylaxis. This analysis allows clinicians to
justify continued treatment for responders identified
within a defined period.
Methods
Study design
A complete description of the methods for the 3-phase,
multicentre, prospective, randomised, controlled PREVA
study has been reported elsewhere [12]. After a 2-week
baseline phase, in which all participants received their indi-
vidualised SoC therapy, patients were randomly assigned
(1:1) to receive nVNS+ SoC or SoC alone during a 4-week
randomised phase. An optional 4-week extension phase
followed, with all patients receiving nVNS + SoC.
Study population
Patients were 18 to 70 years of age and had been diagnosed
with cCH according to International Classification of
Headache Disorders (ICHD) criteria [4] more than 1 year
before enrolment. Patients who had a change in prophylac-
tic medication type or dosage less than 1 month before
enrolment were excluded, as were those with a history of
intracranial/carotid aneurysm, haemorrhage, surgery (e.g.
carotid endarterectomy or vascular neck surgery), syncope,
or seizures. Other key exclusion criteria were significant
head trauma, known or suspected cardiac/cardiovascular
disease, and current implantation with electrical or neuro-
stimulation devices or metallic hardware.
Intervention
Throughout PREVA, no changes in a patient’s prophy-
lactic regimen were allowed. The nVNS-treated patients
self-administered three 2-minute prophylactic stimula-
tions (each separated by a period of 5 min) to the right
side of the neck (right vagus nerve); this preventive
treatment regimen occurred twice daily for a total of 6
stimulations per day. Three additional nVNS stimula-
tions were permitted as needed for the acute treatment
of individual CH attacks. Patients were permitted to re-
ceive abortive medications if their CH attacks persisted
beyond 15 min after stimulation.
End points
Mean weekly attack frequency over time, global percent-
age change from baseline in weekly CH attack frequency
at the end of the randomised phase, and response rates in
the randomised phase were evaluated in this post hoc ana-
lysis. Cut-offs of ≥25%, ≥50%, ≥75%, and 100% reductions
from baseline in attack frequency were used to define re-
sponse. The ≥50% response rate was a secondary end point
of the PREVA study [12]. The remaining response rates
were defined specifically for this post hoc analysis.
Statistical analyses
All end points in this post hoc analysis were evaluated
using a modified intent-to-treat (mITT) population, de-
fined as subjects who had available data for each study
week. For mean weekly attack frequency and global
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percentage change in weekly attack frequency, P values
were derived from the t test. For response rates, P values
were derived from the Fisher exact test or the chi-square
test as appropriate.
Findings
Patients
Complete descriptions of patient disposition, demographics,
and baseline characteristics in PREVA have been reported
previously [12]. A total of 97 patients with cCH were
randomly assigned to receive nVNS+ SoC (n = 48) or SoC
alone (n = 49) (Fig. 1). Demographics, baseline charac-
teristics, and use of prophylactic SoC medications (i.e.
verapamil, lithium, topiramate, and corticosteroids) were
comparable between groups (Table 1). The number of pa-
tients in the mITT population varied among the end points
because of its dependence on the availability of measurable
observations. Of the 92 patients who continued into the ex-
tension phase, 44 continued to receive nVNS+ SoC and 48
switched from SoC alone to nVNS+ SoC.
Weekly attack frequency
The mean weekly attack frequency was significantly
lower with nVNS + SoC than with SoC alone from week
2 of the randomised phase through week 3 of the exten-
sion phase (P < 0.02; Fig. 2). For the nVNS + SoC group,
attack frequencies were significantly reduced from base-
line beginning at week 1 of the randomised phase and
continuing through week 4 of the extension phase (P <
0.05). Attack frequencies were relatively stable through-
out the extension phase.
Global mean attack frequency at the end of the rando-
mised phase had decreased by 40% from baseline in the
nVNS + SoC group and had increased by 1% with SoC
alone, representing a 41% therapeutic benefit of nVNS
(P < 0.001; Fig. 3).
Response rates
At the end of the randomised phase, a significantly
higher percentage of patients in the nVNS + SoC group
than in the SoC group had ≥25%, ≥50%, and ≥75% attack
frequency reductions from baseline (≥25% and ≥50%, P
< 0.001; ≥75%, P = 0.009; Fig. 4). There were 3 patients
(8%) in the nVNS + SoC group who had a 100% attack
frequency reduction; no patients who received SoC alone
had a 100% response.
Safety and tolerability
As previously reported [12], nVNS was safe and well tol-
erated in the PREVA study. There were similar propor-
tions of patients in the nVNS + SoC and SoC groups
who reported ≥1 adverse event. Rates of discontinuation
due to adverse events were also similar between groups.
No serious device-related adverse events occurred.
Discussion
Our post hoc analysis of the PREVA study helps to further
define the possible clinical value of the nVNS efficacy ob-
served in the largest study of cCH prophylaxis to date that
showed significant treatment effects [6, 12]. Significant
beneficial effects were seen with nVNS+ SoC (versus SoC
alone) within 2 weeks after nVNS initiation. The SoC con-
trol group began to experience significant treatment bene-
fits within 1 week after switching to nVNS+ SoC. The
Fig. 1 PREVA Study Design. Abbreviations: nVNS, non-invasive vagus
nerve stimulation; SoC, standard of care
Table 1 PREVA Demographics and Baseline Characteristics
Characteristic nVNS + SoC
(n = 48)
SoC Alone
(n = 49)
Age (y), mean ± SD 45.4 ± 11.0 42.3 ± 11.0
Sex (male), No. (%) 34 (71) 33 (67)
Time since cCH onset (y), mean ± SD 4.7 ± 3.9 5.0 ± 3.7a
CH attack duration (min), mean ± SD
With acute pharmacologic
medications/oxygen
27.4 ± 19.8 29.3 ± 29.9b
Without acute pharmacologic
medications/oxygen
95.2 ± 57.7c 103.3 ± 66.8
Number of CH attacks in the 4
weeks before enrolment, mean ± SD
67.3 ± 43.6c 73.9 ± 115.8
Use of prophylactic CH medications, No. (%)
Verapamil/verapamil hydrochloride 25 (52) 26 (53)
Lithium/lithium carbonate 6 (13) 9 (18)
Topiramate 7 (15) 7 (14)
Corticosteroids 2 (4) 2 (4)
Use of acute CH medications/oxygen, No. (%)
Pharmacologic medications 43 (90) 44 (90)
Oxygen 32 (67) 34 (69)
Abbreviations: CH cluster headache, nVNS non-invasive vagus nerve stimulation,
SD standard deviation, SoC standard of care
aData were missing for 2 patients in the SoC alone group. bData were missing
for 1 patient in the SoC alone group. cData were missing for 1 patient in the
nVNS + SoC group. Adapted with permission from: Gaul C, Diener HC, Silver N,
et al. (2016) Non-invasive vagus nerve stimulation for PREVention and Acute
treatment of chronic cluster headache (PREVA): a randomised controlled study.
Cephalalgia 36:534–546. Copyright 2016 SAGE Publishing
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potential for further benefits with continued nVNS treat-
ment is consistent with findings from several studies [12,
20–23]. Significant reductions from baseline in weekly at-
tack frequency were observed by the end of the first week
of treatment and were sustained until the end of the study
(i.e. week 8). In the 4-week randomised phase, nVNS + SoC
treatment led to a 40% reduction in CH attack frequency,
whereas SoC alone resulted in a 1% increase. The ≥25%,
≥50%, and ≥75% response rates were significantly higher
with nVNS+ SoC than with SoC alone. Limitations of this
analysis are similar to those that have been well docu-
mented for post hoc analyses in general [24].
As important as the statistically significant findings,
nVNS had effects that were clinically meaningful, de-
fined as the ability to provide practical advantages that
address current therapeutic challenges [25]. The excruci-
ating nature of CH attacks warrants a greater sense of
urgency for prophylactic treatment [18, 19] that may be
addressed by nVNS with its rapid onset of efficacy,
which was significant within 2 weeks of nVNS addition
to SoC, and its beneficial effects on ≥25%, ≥50%, ≥75%,
and 100% response rates. For the nVNS + SoC group,
the time to response is as fast as that seen in a previous
clinical study of patients with episodic CH treated with
verapamil, which is also considered to have an early on-
set of effect once therapeutic levels are reached [18, 26].
Nearly half of patients treated with nVNS during the
randomised phase of PREVA experienced a ≥50% re-
sponse, which exceeds the 30% improvement that is
widely accepted by general pain specialists as clinically
meaningful [27–29]. The ≥25% response experienced by
the majority of patients (76%) in the current analysis
would likely also be considered clinically meaningful for
those suffering from the intense pain of cCH.
Our analysis has identified subgroups of patients with
dramatic responses similar to those seen in studies of other
therapies for primary headache [14, 16, 17]. In the nVNS+
SoC group, 8% of patients were attack free for the duration
Fig. 2 Mean Attack Frequencies (mITT Populationa). Abbreviations: CI, confidence interval; mITT, modified intent-to-treat; nVNS, non-invasive vagus
nerve stimulation; SoC, standard of care. a Subjects with available data for each study week. b From the t test
Fig. 3 Global Change in Weekly Attack Frequency at the End of the Randomised Phase (mITT Populationa). Abbreviations: CI, confidence interval;
mITT, modified intent-to-treat; nVNS, non-invasive vagus nerve stimulation; SoC, standard of care. a Subjects with available data for each study
week. b From the t test
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of the randomised phase, and no patients receiving SoC
alone had this result. A ≥75% reduction in weekly attacks
occurred in 22% of patients receiving nVNS+ SoC com-
pared with 2% of patients receiving SoC alone. Further ef-
forts towards identifying potential predictors of such
favourable responses may help to individualise future treat-
ment decisions regarding adjunctive nVNS prophylaxis.
The safety, tolerability, and practicality of nVNS are well
established [12, 22, 23, 30–33]. Based on the frequent
pharmacologic dosing and potentially indefinite treatment
period required for cCH, important challenges of prophy-
laxis include the potential for drug interactions and drug-
related adverse events including atrioventricular conduction
abnormalities, tremor, and confusion [18]. In PREVA, nVNS
was easily incorporated into the existing pharmacologic SoC
regimens without any risk of drug interactions or drug-
related adverse events [12]. The safety and tolerability profile
of nVNS may also help to avoid potential delays in pain re-
lief, as seen in certain patients treated with verapamil, which
requires gradual titration in order to minimize the risk of
third-degree atrioventricular block [18, 34]. The significant
reduction in abortive pharmacologic medication/oxygen use
in the nVNS+ SoC group of PREVA helps to mitigate the
drug-related safety and tolerability, dosing, and portability
challenges of existing acute CH therapies [7, 12, 35, 36].
Although PREVA did not examine the effects of nVNS in
patients with episodic CH, the rapid beneficial effects on at-
tack frequency observed within 2 weeks of treatment initi-
ation in this cCH analysis, combined with the established
safety profile of nVNS, suggest that a trial in episodic CH
would be clinically reasonable.
Conclusions
In this post hoc analysis of attack frequency over time and
expanded response rates, the practical combination of nVNS
and currently available cCH treatments led to rapid, sus-
tained, and clinically meaningful responses. Within 2 weeks
after the addition of prophylactic nVNS to SoC, sustained
reductions in attack frequency were significantly greater
with this combination than with SoC alone. After 4 weeks,
patients’ average weekly attack frequency was 41% lower
with prophylactic nVNS+ SoC treatment than with SoC
alone. The rapid decrease in weekly attack frequency justi-
fies a 4-week trial period to identify responders to nVNS,
with a high degree of confidence, among patients with cCH.
The ≥25%, ≥50%, and ≥75% response rates were significantly
higher with adjunctive nVNS than with SoC alone.
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Fig. 4 Response Rates (mITT Populationa). Abbreviations: mITT, modified intent-to-treat; nVNS, non-invasive vagus nerve stimulation; SoC, standard
of care. a Subjects with available data for each study week. b From the Fisher exact or chi-square test as appropriate
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